Z08

Encounter for follow-up examination after completed treatment for malignant neoplasm

ICD-10 code Z08 is specifically designated for encounters where a patient presents for a follow-up examination after having completed definitive treatment for a malignant neoplasm. This code signifies that the primary purpose of the visit is post-treatment surveillance, distinct from visits involving active cancer treatment or acute management of treatment-related complications. The encounter typically encompasses a comprehensive clinical evaluation, which includes a detailed history, physical examination, and often, specific diagnostic tests such as laboratory work (e.g., tumor markers, complete blood counts, organ function tests) and imaging studies (e.g., CT scans, MRI, PET scans, mammography) tailored to the type of cancer, its stage at diagnosis, and the therapies received. The overarching objectives of these follow-up examinations are multifaceted: early detection of potential cancer recurrence or the development of new primary malignancies, systematic monitoring and management of long-term and late-onset adverse effects of cancer therapies (e.g., neuropathy, lymphedema, cardiovascular toxicity, secondary cancers, cognitive dysfunction, chronic fatigue), assessment of the patient's overall health status and psychosocial well-being, and provision of health education. Such education often includes guidance on lifestyle modifications, symptom recognition, and adherence to recommended screening protocols for other health conditions. The frequency and duration of these surveillance visits are guided by evidence-based clinical guidelines specific to the particular cancer type and patient risk factors, frequently extending for many years, sometimes indefinitely. Appropriate coding necessitates concurrent use of additional ICD-10 codes, such as those detailing the patient's personal history of malignant neoplasm (e.g., Z85.xx) and any specific signs, symptoms, or late effects identified during the examination. This ensures a complete and accurate clinical narrative, highlighting the ongoing importance of meticulous follow-up in the continuum of cancer survivorship care, which plays a pivotal role in optimizing long-term outcomes and quality of life for cancer patients.

Clinical Symptoms

  • Unexplained fatigue
  • New or worsening pain (localized or generalized)
  • Unintended weight loss
  • Appearance of new lumps or swelling
  • Changes in bowel or bladder habits
  • Persistent cough or hoarseness
  • Difficulty swallowing
  • Non-healing sores or unusual skin changes
  • Numbness, tingling, or weakness (neuropathy)
  • Swelling in limbs (lymphedema)
  • Cognitive changes or 'chemo brain'
  • Shortness of breath or respiratory difficulties
  • Cardiac symptoms (e.g., palpitations, chest discomfort)
  • Anxiety, depression, or other mood disturbances

Common Causes

  • Personal history of malignant neoplasm (e.g., breast cancer, colorectal cancer, lung cancer)
  • Completion of definitive cancer treatment (e.g., surgical resection, chemotherapy, radiation therapy, immunotherapy, targeted therapy)
  • Clinical necessity for surveillance of cancer recurrence
  • Requirement for monitoring and management of long-term and late effects of prior cancer treatment
  • Assessment of overall health and functional status post-cancer therapy
  • Implementation of secondary cancer prevention strategies
  • Provision of psychosocial support and survivorship care planning

Documentation & Coding Tips

Clearly document the patient's history of malignant neoplasm, specifying the primary site and confirming that active treatment has been completed. State the purpose of the encounter as surveillance or follow-up after completed definitive therapy.

Example: PATIENT: 62-year-old male presenting for routine 3-month follow-up after completing definitive treatment for Stage II Colon Adenocarcinoma (C18.9) on 03/15/2023. Prior treatment included colectomy and adjuvant chemotherapy, completed as planned. Currently asymptomatic. REVIEW OF SYSTEMS: No weight loss, no changes in bowel habits, no abdominal pain. All negative. PHYSICAL EXAM: Well-appearing, no palpable masses, no lymphadenopathy. Abdomen soft, non-tender, non-distended. LABS: CEA level within normal limits. ASSESSMENT: Z08, Encounter for follow-up examination after completed treatment for malignant neoplasm. Personal history of malignant neoplasm of colon (Z85.038). No evidence of recurrence noted at this time. PLAN: Continue surveillance. Repeat CEA in 3 months. Colonoscopy in 1 year. EDUCATION: Discussed signs/symptoms of recurrence and importance of continued surveillance.

Billing Focus: Explicitly state 'completed treatment' and the specific primary site (e.g., Colon Adenocarcinoma). This differentiates Z08 from active malignancy codes (C-codes). The thorough review of systems, physical exam, and lab/imaging review support the medical necessity and complexity for an appropriate E/M level (e.g., 99214).

Document any ongoing symptoms or complications *related to the previous malignancy or its treatment*, even if no recurrence is found. Differentiate clearly between new issues and those related to cancer history.

Example: PATIENT: 58-year-old female for 6-month follow-up after completed treatment for right breast carcinoma (C50.911) on 06/01/2023. She reports persistent mild right arm lymphedema, stable since last visit, managed with compression sleeve. No new lumps, pain, or systemic symptoms. REVIEW OF SYSTEMS: Complains of mild, chronic right arm swelling (stable). Otherwise negative. PHYSICAL EXAM: Right arm with 1+ pitting edema, stable. No erythema or tenderness. Surgical site well-healed. No palpable axillary or supraclavicular lymphadenopathy. ASSESSMENT: Z08, Encounter for follow-up examination after completed treatment for malignant neoplasm. Personal history of malignant neoplasm of right breast (Z85.3). Secondary lymphedema of right upper limb (I89.0). No evidence of recurrence. PLAN: Continue surveillance. Mammogram (bilateral) in 6 months. Continue lymphedema management with physical therapy and compression. FOLLOW UP: In 6 months.

Billing Focus: Documenting associated conditions like lymphedema (I89.0) provides specificity and supports additional services (e.g., physical therapy, compression supplies). Clearly linking these conditions to the 'Personal history' (Z85.3) demonstrates the ongoing impact of the prior malignancy, justifying medical necessity for associated care and potentially higher E/M coding due to complexity.

Relevant CPT Codes

  • 99214 - Office or Other Outpatient Visit, Est. Patient

    Follow-up examinations for Z08 often involve a detailed review of systems, physical exam, and moderate medical decision making regarding surveillance plans, lab/imaging results, and potential complications. This CPT code appropriately reflects the work involved in assessing a cancer survivor.

  • 99214 - Office or Other Outpatient Visit, Est. Patient

    Primary care physicians (PCPs) frequently manage follow-up care for cancer survivors, especially for stable patients, coordinating with oncology specialists. This E/M level often applies to comprehensive surveillance visits.

  • 77067 - Screening Mammography, Bilateral

    For female patients with a history of breast cancer (Z85.3), routine bilateral screening mammography is a key component of surveillance to detect recurrence or new primary lesions.

  • 72197 - MRI Pelvis, with contrast

    For prostate cancer survivors (Z85.46), pelvic MRI may be used as part of surveillance, particularly in higher-risk cases, to monitor for local recurrence.

  • 45380 - Colonoscopy, with biopsy

    For patients with a history of colorectal cancer (Z85.038), surveillance colonoscopies with biopsies of suspicious areas are often performed to detect metachronous lesions or local recurrence.

  • 82379 - Carcinoembryonic antigen (CEA); serum

    CEA levels are often monitored as a tumor marker in patients with a history of colorectal cancer, providing an indicator of potential recurrence.

  • 84153 - Prostate specific antigen (PSA); total

    PSA levels are crucial for monitoring recurrence in prostate cancer survivors (Z85.46) after definitive treatment.

Related Diagnoses

Hierarchy